|
|
|
eBook/Digital Version available from:
|
Score: 97 |
 |
| AHFS Drug Information 2024 |
|
|
Doody's Core Title (2024 Edition)
|
|
| Score(s): |
|
2.6
(Health Sciences - Pharmacy)
Essential Purchase Title
|
|
|
ISBN: 978-1-58528-721-5,
3504 pages,
Soft Cover
ISBN-10: 1-58528-721-0 |
|
| Copyright: |
2024 |
|
| Edition: |
1st |
|
| Author: |
ASHP |
|
|
Specialties:
|
Pharmacy |
|
| Publisher: |
ASHP |
|
4500 East West Highway |
|
Bethesda, MD 20814 |
|
UNITED STATES |
|
P: 866-279-0681 |
|
http://store.ashp.org |
|
| List Price: |
$491.00 |
|
| Google: |
|
|
|
|
|
|
|
At A Glance
|
Discover the most comprehensive and reliable drug information source with AHFS Drug Information? 2024, a trusted choice on the Doody's Core Titles List from 2020 to 2023. This essential reference is your all-in-one solution for evidence-based therapeutic guidelines and off-label uses, ensuring you have the information you need to protect your patients and enhance your practice. The 2024 edition is thoroughly updated and expanded, featuring over 97,000 references and insights from leading experts. Stay ahead with the latest clinical perspectives, including therapy placement discussions and guideline recommendations. Dive into in-depth coverage of specialty medications for complex, chronic conditions that demand precise handling, monitoring, and dosage adjustments. Explore contemporary topics such as new treatments and vaccines for RSV, safety considerations for GLP-1 agonists, novel orphan drugs, and biosimilars. Gain knowledge on emerging gene therapies and updated vaccine monographs, including pneumococcal, rabies, and RSV vaccines. AHFS DI 2024 also provides crucial information on off-label uses, long-term clinical data, MedWatch alerts, Standardize4Safety initiatives, REMS data, and targeted FDA updates. Additionally, it introduces content on over 175 new molecular entities and therapeutic biological products, with significant revisions on nearly 190 medications. Learn more and order here.
|
|
Reviewer:
|
Yen Dang,
PharmD
(University of Maryland Eastern Shore)
|
|
|
Range
|
Question
|
Score
|
| 1-10 |
Are the author's objectives met? |
10 |
| 1-10 |
Rate the worthiness of those objectives. |
10 |
| 1-5 |
Is this written at an appropriate level? |
5 |
| 1-5 |
Is there significant duplication? (1=significant, 5=insignificant) |
4 |
| 1-5 |
Are there significant omissions? (1=significant, 5=insignificant) |
4 |
| 1-5 |
Rate the authority of the authors. |
5 |
| 1-5 |
Are there sufficient illustrations? |
N/A |
| 1-5 |
Rate the pedagogic value of the illustrations. |
N/A |
| 1-5 |
Rate the print quality of the illustrations. |
N/A |
| 1-5 |
Are there sufficient references? |
N/A |
| 1-5 |
Rate the currency of the references. |
N/A |
| 1-5 |
Rate the pertinence of the references. |
N/A |
| 1-5 |
Rate the helpfulness of the index. |
5 |
| 1-5 |
If important in this specialty, rate the physical appearance of the book |
N/A |
| 1-10 |
Is this a worthwhile contribution to the field? |
10 |
| 1-10 |
If this is a 2nd or later edition, is this new edition needed? |
10 |
|
|
|
Reviewer:
|
Yen Dang,
PharmD
(University of Maryland Eastern Shore)
|
|
|
Description
|
| This book provides a comprehensive, up-to-date guide for drug information. It is a federally recognized official compendium for establishing safe and effective drug use standards. The edition covers monographs of drugs that are commonly prescribed, drugs used as first-line therapy for treatment regimens, drugs that have a broad range of established uses, and drugs with unique roles. |
|
|
Purpose
|
| The book's purpose is to provide evidence-based information about safe and effective drug therapy through drug monographs. These are worthy objectives as it contains independent, non-commercial evaluations of drug therapy that is not under the influence of pharmaceutical companies and third parties. The book meets its objectives as the drug monographs are prepared by professional editorial and analytical staff who evaluate published evidence for each drug. |
|
|
Audience
|
| The book's audience is all healthcare practitioners and students who are looking for up-to-date and unbiased drug information. It meets the needs of its audience as the book is continuously updated and revised based on uses, therapeutic perspectives, cautions, drug interactions, and new products. The publishers are reputable, and the book is a highly recognized authority adopted by many healthcare organizations. |
|
|
Features
|
| The book provides full-length drug monographs including drug descriptions, REMS, uses, dosage and administration, cautions, toxicity, drug interactions, laboratory tests, pharmacology, mechanism of action, pharmacokinetics, chemistry and stability, preparations, and references. Certain monographs are designated as AHFS firstReleases, which are descriptions of new molecular entities from the manufacturer's labeling. Additionally, there are some monographs with Overviews which include summary descriptions from the manufacturer's labeling and clinical studies that allowed for the approval of the drug. Certain monographs have SumMons which are summary descriptions about a drug from the manufacturer's labeling and other pertinent sources of information. |
|
|
Assessment
|
| The book is a highly recognized authority of drug information. It is updated every year to include new information about existing and novel drugs. The updates in this edition contain clinical perspective sections, expanded coverage of specialty medications, contemporary topics, vaccine monographs, off-label uses, MedWatch alerts, and new molecular entities and therapeutic biological products. |
|
|
|
|
|
|
|
|
